Tocilizumab in COVID-19 interstitial pneumonia.

G PomponioA FerrariniM BonifaziM MorettiA SalviA GiacomettiM TavioG TitoloL MorbidoniG FrausiniM OnestaD AmicoM L B RocchiS MenzoL ZuccatostaF MeiV MendittoS SvegliatiA DonatiM M D'ErricoM PavaniArmando Gabrielli

Published in: Journal of internal medicine (2021)

Objective clinical response rate overcame the pre-defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
rheumatoid arthritis patients
coronavirus disease
sars cov
disease activity
respiratory tract
respiratory syndrome coronavirus